BridgeBio Pharma Operating Income 2018-2024 | BBIO
BridgeBio Pharma operating income from 2018 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
BridgeBio Pharma Annual Operating Income
(Millions of US $) |
| 2023 |
$-607 |
| 2022 |
$-512 |
| 2021 |
$-577 |
| 2020 |
$-474 |
| 2019 |
$-266 |
| 2018 |
$-184 |
| 2017 |
$-44 |
BridgeBio Pharma Quarterly Operating Income
(Millions of US $) |
| 2024-09-30 |
$-192 |
| 2024-06-30 |
$-176 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$-177 |
| 2023-09-30 |
$-158 |
| 2023-06-30 |
$-146 |
| 2023-03-31 |
$-126 |
| 2022-12-31 |
$-129 |
| 2022-09-30 |
$-129 |
| 2022-06-30 |
$-80 |
| 2022-03-31 |
$-174 |
| 2021-12-31 |
$-166 |
| 2021-09-30 |
$-149 |
| 2021-06-30 |
$-94 |
| 2021-03-31 |
$-168 |
| 2020-12-31 |
$-127 |
| 2020-09-30 |
$-120 |
| 2020-06-30 |
$-125 |
| 2020-03-31 |
$-102 |
| 2019-12-31 |
$-79 |
| 2019-09-30 |
$-55 |
| 2019-06-30 |
$-69 |
| 2019-03-31 |
$-64 |
| 2018-12-31 |
|
| 2018-09-30 |
$-41 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
